Literature DB >> 17976362

Sarcoma.

Keith M Skubitz1, David R D'Adamo.   

Abstract

Sarcomas comprise a heterogeneous group of mesenchymal neoplasms. They can be grouped into 2 general categories, soft tissue sarcoma and primary bone sarcoma, which have different staging and treatment approaches. This review includes a discussion of both soft tissue sarcomas (malignant fibrous histiocytoma, liposarcoma, leiomyosarcoma, synovial sarcoma, dermatofibrosarcoma protuberans, angiosarcoma, Kaposi sarcoma, gastrointestinal stromal tumor, aggressive fibromatosis or desmoid tumor, rhabdomyosarcoma, and primary alveolar soft-part sarcoma) and primary bone sarcomas (osteosarcoma, Ewing sarcoma, giant cell tumor, and chondrosarcoma). The 3 most important prognostic variables are grade, size, and location of the primary tumor. The approach to a patient with a sarcoma begins with a biopsy that obtains adequate tissue for diagnosis without interfering with subsequent optimal definitive surgery. Subsequent treatment depends on the specific type of sarcoma. Because sarcomas are relatively uncommon yet comprise a wide variety of different entities, evaluation by oncology teams who have expertise in the field is recommended. Treatment and follow-up guidelines have been published by the National Comprehensive Cancer Network (www.nccn.org).

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17976362     DOI: 10.4065/82.11.1409

Source DB:  PubMed          Journal:  Mayo Clin Proc        ISSN: 0025-6196            Impact factor:   7.616


  80 in total

Review 1.  Modeling sarcomagenesis using multipotent mesenchymal stem cells.

Authors:  Rene Rodriguez; Ruth Rubio; Pablo Menendez
Journal:  Cell Res       Date:  2011-09-20       Impact factor: 25.617

2.  Positron emission tomography for the evaluation of soft-tissue sarcomas and bone sarcomas.

Authors:  Cristina Nanni; Maria Cristina Marzola; Domenico Rubello; Stefano Fanti
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-12       Impact factor: 9.236

3.  High-frequency canonical Wnt activation in multiple sarcoma subtypes drives proliferation through a TCF/β-catenin target gene, CDC25A.

Authors:  Sapna Vijayakumar; Guizhong Liu; Ioana A Rus; Shen Yao; Yan Chen; Gal Akiri; Luca Grumolato; Stuart A Aaronson
Journal:  Cancer Cell       Date:  2011-05-17       Impact factor: 31.743

4.  Ewing's sarcoma: A case report of a 52-year-old woman with recurrent tumor and literature review.

Authors:  Waseem Khaliq; Mohammad Farshad Bahador; Thomas Nichols Laurence; Ronald Andrew Sapiente; James Sheridan Lewis; David Lee Graham
Journal:  Oncol Lett       Date:  2011-10-13       Impact factor: 2.967

5.  Ewing's sarcoma family of tumors of the maxillary sinus: a case report of multidisciplinary examination enabling prompt diagnosis.

Authors:  Shogo Tajima; Aki Ohkubo; Matsumi Yoshida; Kenji Koda; Ichirota Nameki
Journal:  Int J Clin Exp Pathol       Date:  2015-01-01

6.  Proximal ulna endoprosthetic replacement for bone tumours in young patients.

Authors:  Mathew D Sewell; Sammy A Hanna; Rob C Pollock; William J Aston; John A Skinner; Gordon W Blunn; Stephen R Cannon; Timothy W R Briggs
Journal:  Int Orthop       Date:  2012-05       Impact factor: 3.075

7.  Soft Tissue Sarcoma of the Extremities: What Is the Value of Treating at High-volume Centers?

Authors:  Alexander L Lazarides; David L Kerr; Daniel P Nussbaum; R Timothy Kreulen; Jason A Somarelli; Dan G Blazer; Brian E Brigman; William C Eward
Journal:  Clin Orthop Relat Res       Date:  2019-04       Impact factor: 4.176

8.  Gene expression profiling identifies inflammation and angiogenesis as distinguishing features of canine hemangiosarcoma.

Authors:  Beth A Tamburini; Tzu L Phang; Susan P Fosmire; Milcah C Scott; Susan C Trapp; Megan M Duckett; Sally R Robinson; Jill E Slansky; Leslie C Sharkey; Gary R Cutter; John W Wojcieszyn; Donald Bellgrau; Robert M Gemmill; Lawrence E Hunter; Jaime F Modiano
Journal:  BMC Cancer       Date:  2010-11-09       Impact factor: 4.430

9.  The epidemiology of bone cancer in 0 - 39 year olds in northern England, 1981 - 2002.

Authors:  Rachel Eyre; Richard G Feltbower; Peter W James; Karen Blakey; Emmanuel Mubwandarikwa; David Forman; Patricia A McKinney; Mark S Pearce; Richard J Q McNally
Journal:  BMC Cancer       Date:  2010-07-06       Impact factor: 4.430

10.  MFH revisited: outcome after surgical treatment of undifferentiated pleomorphic or not otherwise specified (NOS) sarcomas of the extremities -- an analysis of 140 patients.

Authors:  Marcus Lehnhardt; Adrien Daigeler; Heinz H Homann; Vanessa Schwaiberger; Ole Goertz; Cornelius Kuhnen; Hans U Steinau
Journal:  Langenbecks Arch Surg       Date:  2008-06-27       Impact factor: 3.445

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.